Clinical Trials Browser

Suspended × Triple Negative Breast Neoplasms × Clear all

NCT05111561 2026-03-17

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1 Suspended

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07136493 2026-03-05

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

Phase NA Suspended

Triple Negative Breast Neoplasms

NCT02993068 2026-02-19

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Phase NA Suspended

Triple Negative Breast Neoplasms

NCT05989828 2026-01-14

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Phase 1 Suspended

Triple Negative Breast Neoplasms

NCT05958199 2025-06-27

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Phase 1 Suspended

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04803084 2024-11-20

Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03002103 2023-04-26

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Phase 3 Suspended

Triple Negative Breast Neoplasms

NCT04250818 2021-05-19

Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03777579 2019-08-08

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Phase 3 Suspended

Triple Negative Breast Neoplasms